Component

Hepatitis B virus RNA production

Viral RNA output, which fell before viral protein and particle output in the time course.

4 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. (−)-Lariciresinol blocked hepatitis B virus RNA production first, followed by viral proteins, then viral particles and DNA.

    (-)-Lariciresinol → Hepatitis B virus RNA production source_derived_draftungraded
    Experimental context and source evidence
    duration
    Time course, order established by sequence of loss
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    Hepatoma cell lines carrying hepatitis B virus
    exposure
    (−)-Lariciresinol isolated from the roots of Isatis indigotica
    limitations
    The order of events is what the time course establishes; the abstract does not give the concentrations at which each step was measured.
    organism
    Hepatoma cell lines carrying hepatitis B virus
    plain_language
    (−)-Lariciresinol blocked hepatitis B virus RNA production first, followed by viral proteins, then viral particles and DNA.
    primary_references
    Anti-Hepatitis B Virus Activity of (-)-Lariciresinol Isolated from the Roots of Isatis indigotica. (2022). https://pubmed.ncbi.nlm.nih.gov/35630700/ DOI: 10.3390/molecules27103180
    route
    In vitro
    tissue
    Viral RNA, protein and particle production in order of appearance

    Lariciresinol: five molecules under one name, and the mechanisms each one carries (2026-09-22) · lines 77–86

    Original AI-assisted curation of twelve primary studies, every abstract read and all DOIs cross-checked against live PubMed metadata. Mechanism edges only, with no conclusion or claim of benefit recorded. Three author clusters account for eight of the twelve and carry shared laboratory keys. Study-specific concentrations, negative findings and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft

    ## minus-lariciresinol-lowers-hepatitis-b-rna (−)-Lariciresinol blocked hepatitis B virus RNA production first, followed by viral proteins, then viral particles and DNA. Model/species: Hepatoma cell lines carrying hepatitis B virus Tissue/system: Viral RNA, protein and particle production in order of appearance Exposure: (−)-Lariciresinol isolated from the roots of Isatis indigotica Route: In vitro Duration: Time course, order established by sequence of loss Limits: The order of events is what the time course establishes; the abstract does not give the concentrations at which each step was measured. Primary reference: Anti-Hepatitis B Virus Activity of (-)-Lariciresinol Isolated from the Roots of Isatis indigotica. (2022). https://pubmed.ncbi.nlm.nih.gov/35630700/ DOI: 10.3390/molecules27103180 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. Combining RNA sequencing analysis, the decrease in hepatitis B virus transcriptional activity by (-)-lariciresinol was reported as possibly related to hepatocyte nuclear factor 1 alpha, and the compound was described as inhibiting replication by regulating HNF1α-mediated transcription.

    (-)-Lariciresinol → Human hepatocyte nuclear factor 1 alpha / HNF1A source_derived_draftungraded
    Experimental context and source evidence
    duration
    Not stated here
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    Hepatoma cells carrying hepatitis B virus, with RNA sequencing
    exposure
    (-)-Lariciresinol isolated from the roots of Isatis indigotica
    limitations
    The abstract hedges the link as one that may be related, and states regulation without giving a direction, a magnitude or a concentration, so no direction is recorded. No knockdown or over-expression rescue of HNF1α is described in the abstract, so the relationship is associative rather than demonstrated as necessary.
    organism
    Hepatoma cells carrying hepatitis B virus, with RNA sequencing
    plain_language
    Combining RNA sequencing analysis, the decrease in hepatitis B virus transcriptional activity by (-)-lariciresinol was reported as possibly related to hepatocyte nuclear factor 1 alpha, and the compound was described as inhibiting replication by regulating HNF1α-mediated transcription.
    primary_references
    (-)-Lariciresinol Isolated from the Roots of Isatis indigotica Fortune ex Lindl. Inhibits Hepatitis B Virus by Regulating Viral Transcription. (2022). https://pubmed.ncbi.nlm.nih.gov/35630700/ DOI: 10.3390/molecules27103223
    route
    In vitro
    tissue
    Host transcription factor and viral transcriptional activity

    (-)-Lariciresinol and hepatocyte nuclear factor 1 alpha: the host-factor step (2026-09-22) · lines 11–20

    Original AI-assisted curation of twelve primary studies, every abstract read and all DOIs cross-checked against live PubMed metadata. Mechanism edges only, with no conclusion or claim of benefit recorded. Three author clusters account for eight of the twelve and carry shared laboratory keys. Study-specific concentrations, negative findings and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft

    ## minus-lariciresinol-regulates-hnf1-alpha Combining RNA sequencing analysis, the decrease in hepatitis B virus transcriptional activity by (-)-lariciresinol was reported as possibly related to hepatocyte nuclear factor 1 alpha, and the compound was described as inhibiting replication by regulating HNF1α-mediated transcription. Model/species: Hepatoma cells carrying hepatitis B virus, with RNA sequencing Tissue/system: Host transcription factor and viral transcriptional activity Exposure: (-)-Lariciresinol isolated from the roots of Isatis indigotica Route: In vitro Duration: Not stated here Limits: The abstract hedges the link as one that may be related, and states regulation without giving a direction, a magnitude or a concentration, so no direction is recorded. No knockdown or over-expression rescue of HNF1α is described in the abstract, so the relationship is associative rather than demonstrated as necessary. Primary reference: (-)-Lariciresinol Isolated from the Roots of Isatis indigotica Fortune ex Lindl. Inhibits Hepatitis B Virus by Regulating Viral Transcription. (2022). https://pubmed.ncbi.nlm.nih.gov/35630700/ DOI: 10.3390/molecules27103223 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

  2. Promoter reporter assays and RNA decay dynamics indicated the hepatitis B virus RNA reduction was mainly transcriptional rather than a change in RNA stability.

    (-)-Lariciresinol → Hepatitis B virus promoter activity source_derived_draftungraded
    Experimental context and source evidence
    duration
    Not stated here
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    Hepatoma cells with promoter luciferase reporters, with an RNA decay experiment
    exposure
    (−)-Lariciresinol
    limitations
    The two designs together separate transcription from decay; neither measures covalently closed circular DNA.
    organism
    Hepatoma cells with promoter luciferase reporters, with an RNA decay experiment
    plain_language
    Promoter reporter assays and RNA decay dynamics indicated the hepatitis B virus RNA reduction was mainly transcriptional rather than a change in RNA stability.
    primary_references
    Anti-Hepatitis B Virus Activity of (-)-Lariciresinol Isolated from the Roots of Isatis indigotica. (2022). https://pubmed.ncbi.nlm.nih.gov/35630700/ DOI: 10.3390/molecules27103180
    route
    In vitro
    tissue
    Viral promoter activity versus RNA decay rate

    Lariciresinol: five molecules under one name, and the mechanisms each one carries (2026-09-22) · lines 88–97

    Original AI-assisted curation of twelve primary studies, every abstract read and all DOIs cross-checked against live PubMed metadata. Mechanism edges only, with no conclusion or claim of benefit recorded. Three author clusters account for eight of the twelve and carry shared laboratory keys. Study-specific concentrations, negative findings and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft

    ## minus-lariciresinol-acts-on-transcription-not-rna-decay Promoter reporter assays and RNA decay dynamics indicated the hepatitis B virus RNA reduction was mainly transcriptional rather than a change in RNA stability. Model/species: Hepatoma cells with promoter luciferase reporters, with an RNA decay experiment Tissue/system: Viral promoter activity versus RNA decay rate Exposure: (−)-Lariciresinol Route: In vitro Duration: Not stated here Limits: The two designs together separate transcription from decay; neither measures covalently closed circular DNA. Primary reference: Anti-Hepatitis B Virus Activity of (-)-Lariciresinol Isolated from the Roots of Isatis indigotica. (2022). https://pubmed.ncbi.nlm.nih.gov/35630700/ DOI: 10.3390/molecules27103180 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

  3. (−)-Lariciresinol inhibited hepatitis B virus DNA replication of both wild-type and nucleoside analogue resistant strains.

    (-)-Lariciresinol → Hepatitis B virus DNA replication source_derived_draftungraded
    Experimental context and source evidence
    duration
    Not stated here
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    Hepatoma cells carrying wild-type and nucleos(t)ide-analogue-resistant hepatitis B virus
    exposure
    (−)-Lariciresinol
    limitations
    Activity against resistant strains is consistent with a host target rather than the viral polymerase; the abstract does not itself demonstrate the host target is necessary.
    organism
    Hepatoma cells carrying wild-type and nucleos(t)ide-analogue-resistant hepatitis B virus
    plain_language
    (−)-Lariciresinol inhibited hepatitis B virus DNA replication of both wild-type and nucleoside analogue resistant strains.
    primary_references
    Anti-Hepatitis B Virus Activity of (-)-Lariciresinol Isolated from the Roots of Isatis indigotica. (2022). https://pubmed.ncbi.nlm.nih.gov/35630700/ DOI: 10.3390/molecules27103180
    route
    In vitro
    tissue
    Viral DNA replication

    Lariciresinol: five molecules under one name, and the mechanisms each one carries (2026-09-22) · lines 99–108

    Original AI-assisted curation of twelve primary studies, every abstract read and all DOIs cross-checked against live PubMed metadata. Mechanism edges only, with no conclusion or claim of benefit recorded. Three author clusters account for eight of the twelve and carry shared laboratory keys. Study-specific concentrations, negative findings and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft

    ## minus-lariciresinol-inhibits-resistant-hbv-strains (−)-Lariciresinol inhibited hepatitis B virus DNA replication of both wild-type and nucleoside analogue resistant strains. Model/species: Hepatoma cells carrying wild-type and nucleos(t)ide-analogue-resistant hepatitis B virus Tissue/system: Viral DNA replication Exposure: (−)-Lariciresinol Route: In vitro Duration: Not stated here Limits: Activity against resistant strains is consistent with a host target rather than the viral polymerase; the abstract does not itself demonstrate the host target is necessary. Primary reference: Anti-Hepatitis B Virus Activity of (-)-Lariciresinol Isolated from the Roots of Isatis indigotica. (2022). https://pubmed.ncbi.nlm.nih.gov/35630700/ DOI: 10.3390/molecules27103180 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards